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A R T I C L E I N F O A B S T R A C T
1. Introduction
Background : Rheumatic heart disease (RHD) contributed to a large number of proportion amoung cardiovascular 
problems in developing county, especially Indonesia. Secondary prophylaxis method using intramuscular 
injection of Benzathin Penicillin-G (BPG) has been known as the most effective strategy in the prevention of RHD. 
However, whether this prevention method also resulting in prevention of disease severity in Indonesian patients 
remained to be examined.
Objectives : This study aimed to assess the difference of rheumatic valve severity in Indonesian pediatric patients 
between adequate and poor adherence to secondary prophylaxis by using intramuscular BPG injection.
Methods : This cross-sectional study was conducted at Pediatric Cardiology Department of Saiful Anwar General 
Hospital from November 2018 to June 2019. Patients with documented history of RHD were included. Frequency 
of intramuscular BPG injection during the last one year was recorded. Adherence was measured using the propor-
tion of days covered (PDC) and adequate adherence was defined as PDC ≥0.90. The severity of RHD was 
assessed based on the severity of the mitral and / or aortic valve using echocardiography. Bivariate analysis and 
multivariate logistic regression analysis was used to identify characteristics associated with rheumatic valve 
severity.
Results : A significant difference of rheumatic mitral and/or aortic valve severity  was observed between adequate 
adherence compared to poor adherence group (p = 0.016). Rheumatic mitral and/or aortic valve were found to 
be more severe in patients who has one or more episode of ARF recurrence (p = 0.003). Multivariate logistic 
regression analysis demonstrated that adherence to secondary prophylaxis within the last 1 year has the strongest 
influence on the severity of rheumatic mitral and/or aortic valve (p = 0.049; OR 7.20).
Conclusion : The adherence to secondary prophylaxis has the strongest related the rheumatic valve severity 
compared to other factors. 
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 Rheumatic heart disease (RHD) is one of the most leading 
cause of morbidity and mortality of cardiovascular disease in the 
world.1 RHD occurs as a complication of acute rheumatic fever (ARF), 
35% of patients diagnosed with ARF developed RHD after 1 year and 
the rate increased to 51% after 10 years. The incidence of ARF in 
children aged 5-14 years ranges from 300,000-350,000 per year. 
Therefore, the the risk of RHD raised when the incidence of ARF also 
high in the population.2-4 
 
 Secondary prophylaxis using intramuscular BPG injection 
has been known as an effective treatment to prevent recurrence of ARF 
and to prevent the development of RHD for more than six decades.1,5 
There are still limited references and studies in RHD patients receiving 
secondary prophylaxis therapy.6 It remains unclear whether secondary 
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prophylaxis adherence using intramuscular BPG injection would 
contribute to significant difference of outcome especially in terms of 
rheumatic valve severity in Indonesia.
2. Methods
 This was an observational analytic study with cross-sectional 
echocardiographic as end point. Data was also obtained from 
outpatient medical record at Pediatric Cardiology Clinic.  History taking 
regarding the compliance to BPG injection recorded via phone or direct 
interview. 
 The severity of valve abnormalities was assessed using 
echocardiography. Echocardiography was performed by cardiology 
residents under supervision of pediatric cardiologist who were experi-
enced in RHD cases. We evaluated valve severity based on quantitative 
and semi-quantitative methods according to the recommendations of 
the European Association of Echocardiography for the assessment of 
valvular regurgitation (2010) and European Association of Echocardi-
ography / American Society of Echocardiography assessment of valve 
stenosis (2009).7,8 We divided the valve severity of RHD into 3 groups 
i.e mild, moderate, and severe. This classification was made based on 
rheumatic mitral and/or aortic valve severity according to the Austra-
lian Guideline for Prevention, Diagnosis and Management of Acute 
Rheumatic Fever and Rheumatic Heart Disease (2012).9
 Adherence was measured using the proportion of days 
covered (PDC) by intramuscular BPG injection. Adequate adherence 
was defined as PDC ≥0.90.10 We divided into 2 groups which were 
adequate adherence and poor adherence groups, based on the 
adherence to secondary prophylaxis. Every day of delays from 
scheduled injection could illustrate the risk of ARF recurrence and the 
risk of elaborating rheumatic heart valve abnormalities.
 The study protocols were conducted in accordance with the 
Declaration of Helsinki and were approved by the Institutional Review 
Board, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia. 
The aims, risks, and benefits of the study were explained to each 
participant, and they were asked to sign an informed consent form 
prior to enrollment. Participants were also informed that they could 
quit at any time during the interview session. Participations in this 
study were voluntary and no incentive was given.
3. Results
3.1. Patients selection
 During November 2018 to June 2019, there were 47 out of 
69 pediatric patients diagnosed with RHD who met the inclusion and 
exclusion study criteria. Twenty-two patients were excluded due to 
incomplete data, the use of oral secondary prophylaxis, or showing no 
mitral or aortic valve abnormalities during echocardiography. Other 
exclusion criteria were congenital heart disease, infective endocarditis, 
history of valve surgery, and hemodynamic changes due to volume 
depletion or overload.
3.2. Baseline characteristics
 There was no predominance in sex proportion between 
samples (51.1% male vs. 48.9% female). The mean age of samples were 
11.74 years in mild RHD group, 12.43 years in moderate RHD group 
and 12.5 years in severe RHD group. The first detection of RHD was 
diagnosed within approximately 9 years old among all groups. The mild 
RHD group was shown the highest mean body weight (approximately 
36 kgs). The nutritional status of patients was mostly normal (55.3%), 
while the remaining sample were underweight (27.7%) and overweight 
(17%) Patients who received ACE inhibitors were 25.5% of total 
sample. The duration of secondary prophylaxis treatment ranged from 
12 months to 90 months (mean 33 months) in all RHD groups. There 
was a total 21.3% of ARF recurrence, and the highest Wilkins score 
were found in severe RHD group, only 2.1% of sample suffered from 
severe remodeling according to wilkins score category, as shown in 
table 1.
Table 1. Baseline characteristics of patients included in our study
3.3. Main findings
 Patients with adequate adherence to secondary prophylaxis 
in the last 1-year were found to experience mild RHD (66.7%), 
compared to patients with poor adherence who found to be moderate 
(45%) and severe RHD (30%). There is a significant difference between 
adequate compared to poor adherence group in terms of rheumatic 
valve severity (p = 0.016), see table 2.
 Bivariate analysis showed that valve severity was statistically 
different when ARF re-occurred   and the Wilkins score was higher (p = 
0.003; p = 0.000, respectively), see table 3. No significant in valve 
severity in term of age, sex, nutritional status or treatment duration.
 Multivariate analysis between adherence to secondary 
prophylaxis, total ARF recurrence, and Wilkins scores showed that the 
adherence to secondary prophylaxis variable has the strongest related 
to the severity of RHD (p = 0.049; OR 7.20) compared to others as 
shown in table 4.
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Patient characteristic 
 
Total 
(n=47) 
 
Sex 
Man 
Woman 
 
24 (51,1%) 
23 (48,9%) 
Age (years) (mean ± sd)  
Mild RHD 11,74 ± 3,44 
Moderate RHD 12,43 ± 2,10 
Severe RHD 12,50 ± 1,72 
Age at RHD diagnostic (years) (mean ± sd)  
Mild RHD 9,04 ± 3,80 
Moderate RHD 9,71 ± 2,19 
Severe RHD 9,40 ± 2,46 
Weight (mean ± sd)  
Mild RHD 36,17 ± 11,75 
Moderate RHD 33,38 ± 17,94 
Severe RHD 32,70 ± 7,60 
Treatment duration  (mean ± sd)  
Mild RHD 33,56 ± 19,56 
Moderate RHD 33,21 ± 16,28 
Severe RHD 34,90 ± 21,75 
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Adherence 
RHD severity  
Total P value 
Mild Moderate Severe 
Good Adherence  18 (66,7%)  5 (18,5%) 4 (14,8%) 27 (100%) 
0,016* 
Poor Adherence 5 (25%) 9 (45%) 6 (30%) 20 (100%) 
Table 2. The effect of adding G. mangostana L. extract on lipid and glycemic profiles after 90 days of treatment
Table 3. Bivariate Analysis
Table 4. Logistic Regression
Variables in the equation  
Adherence 
RHD severity  
Total P value 
Mild Moderate Severe 
Sex    24 (100%) 0,336 
  23 (100%) 
ARF 
recurrence in 
1 year 
   43 (100%) 0,419 
   4 (100%) 
Total ARF
recurrence 
   37 (100%) 0,003** 
   10 (100%) 
Nutritional 
status 
   13 (100%) 0,176 
   26 (100%) 
   8 (100%) 
Wilkins score         0,000** 
Wilkins score 
categorical  
   46 (100%) 0,157 
   1 (100%) 
Ace Inhibitor
     35 (100%) 0,121 
  12 (100%) 
Treatment 
duration 
   0,985 
Age         0,818 
7 (29,2%)
3 (13%)
9 (20,9%)
1 (25%)
5 (13,5%)
5 (50%)
3 (23,1%)
7 (26,9%)
0 (0%)
3,1 ± 1,20
9 (19,6%)
1 (100%)
7 (20%)
3 (25%)
34,90±21,7
9,40 ± 2,46
6 (25%)
8 (34,8%)
12 (27,9%)
2 (50%)
10 (27%)
4 (30%)
7 (53,8%)
4 (15,4%)
3 (37,5%)
1,07 ± 1,21
14 (30,4%)
0 (0%)
8 (22,9%)
6 (50%) 
33,21±16,2
9,71 ± 2,19
11 (45,8%)
12 (52,2%)
22 (51,2%)
1 (25%)
22 (59,5%)
1 (10%)
3 (23,1%)
15 (57,7%)
5 (62,5%)
0 ± 0
23 (50%)
0 (0%)
20 (57,1%)
3 (25%)
33,56±19,5
9,04 ± 3,80
Woman
Man 
Never
1x
Never
1x
Underweight
Normal
Overweight
Mild 
Remodeling
Severe 
Remodeling
No
Yes 
 
 B S.E. Wald df Sig. Exp(B) 
95% C.I.for EXP(B)
Lower Upper 
Step 1a 
Adherence90(1) 1.910 1.067 3.202 1 .074 6.750 .834 54.663
TotalRecurrence(1) .288 1.607 .032 1 .858 1.333 .057 31.121 
WilkinScore 19.840 4006.255 .000 1 .996 413289521.710 .000 . 
Constant - 2.197 .745 8.690 1 .003 .111   
Step 2a 
Adherence90(1) 1.974 1.003 3.875 1 .049 7.200 1.009 51.392 
WilkinScore 19.961 .000 1 .996 466789367.757 .000 . 
Constant -2.197 .745 8.690 1 .003 .111   
Note; a. Variable(s) entered on step 1: Adherence 90, Total ARF recurrence, Wilkins Score.
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4. Discussion
4.1. Adherence to Secondary Prophylaxis and the Severity of RHD
 Twenty-seven patients (57.4%) demonstrated adequate 
adherence to secondary prophylaxis treatment (PDC ≥0.90), whilst 20 
patients (42.6%) showed poor adherence (PDC rate was <0.90). Rates 
of secondary prophylactic treatment adherence varied greatly in various 
studies, previous study using a cut-off point of  ≥0.90 in Brazil showed 
a total adequate adherence in 71.9% of patients.10 Gasse et al. obtained 
a total adequate adherence in 54% patients by using cut-off of 
adherence  ≥0.80.12 However, Culliford-Semmens et al. reported 
adequate adherence of 68.4% patients in New Zealand using the same 
cut-off.5 Rahmawaty et al. has suggested a total adequate adherence in 
58.7% patients, but the cut-off rate used did not clearly state.13 Accord-
ing to previous data it was suggested that our result was concurrence to 
other. We did not explore further related factors affecting poor compli-
ance in this study.
 In contrast to several previous studies which showed a 
significant difference in valve severity by using an adherence cut-off ≥
0.80, this study provides higher adherence (≥0.90) in order to achieve 
more significant value between mild, moderate, and severe RHD. Based 
on our data that used a 0.90 adherence cut-off point, the result showed 
that patients with adequate adherence to secondary prophylactic 
treatment in the last 1-year experienced milder RHD (66.7%), while 
patients with poor adherence had more moderate RHD (45%) and even 
more severe RHD (30%). Further study is warranted to explore the 
need of higher cut off adherence in Indonesian children correlate to 
genetic susceptibility or high prevalence in crowded population with 
poor individual hygine or other factors.  
 The Bivariate analysis using chi-square test demonstrated a 
significant relationship between the level of adherence to secondary 
prophylaxis with the severity of RHD valve abnormalities (p = 0.016). 
This result emphasized the need to increase adherence to secondary 
prophylaxis for RHD patients in Indonesia to prevent more severe valve 
disease. Concurrence to our study, Stewart et al. have mentioned a 
trend towards higher adherence was seen among children, more 
frequent clinic attendees, and patients with less severe disease. No 
trend was seen between adherence rates in men and women.15 Remond 
et al. also suggested the importance of register / recall systems, dedicat-
ed  health  teams  for  delivery  of  secondary  antibiotic  prophylaxis, 
education about ARF and RHD, linkages with the community, and 
strong staff–patient relationships to improve compliance.14 Rheumatic 
fever registries have gained considerable popularity as a means of 
improving treatment adherence. The World Health Organization has 
promoted the use of ARF registers in developing countries to attempt to 
coordinate patient management and improve adherence to secondary 
prophylaxis.15,16
 This study result was consistent with many studies which 
stated that routine secondary prophylaxis followed by adherence to 
treatment is closely related to the low degree of valve severity. Sanyal 
et al. in India mentioned that 33% of children with ARF and carditis 
have shown resolution of heart murmur after 5 years of BPG secondary 
prophylaxis.17 Atatoa-Carr et al. also mentioned that the administration 
of secondary prophylaxis could reduce the severity of RHD and was 
associated with regression of heart valve abnormalities in about 50-70% 
of patients with adequate adherence for a decade.18 There were similar-
ities between our study and other previous studies that poor adherence 
to secondary prophylaxis was associated with more severe valve 
abnormalities. Unfortunately, because our study only evaluated 
echocardiography once in a row, it was unable to assess regression or 
progression of valve abnormalities.
4.2. ARF Recurrence and RHD Severity
 Bivariate analysis between the ARF recurrence in the last 
1-year (without secondary prophylaxis) and the severity of RHD 
showed no significant relationship (p = 0.419). However, further 
bivariate analysis between the total ARF recurrence (after the adminis-
tration of secondary prophylaxis treatment) and the severity of RHD 
found a significant relationship (p = 0.003). This can be explained by a 
very low recurrence rate of ARF in the last 1-year which only found in 4 
patients (8.5%) before the treatment of secondary prophylaxis. Howev-
er, after the administration of secondary prohylaxis, the total ARF 
recurrence rate was found in 10 patients (21.3%). Although not a big 
count, but it was statistically significant after using Fisher exact test, 
suggesting that this phenomenon was caused by a small size of sample. 
Further bigger sample might confirm the correlation between 
recurrence of RF with RHD valve severity.
4.3. Wilkins score and RHD severity
 Bivariate analysis between the Wilkins scores and the 
severity of RHD demonstrated a significant relationship (p = 0.000). 
The Wilkins score was calculated numerically based on the total score 
of four parameters (leaflet mobility, valvular thickening, leaflet calcifi-
cation, and subvalvular thickening).19 Further analysis was attempted 
using the categorical Wilkins score, which divided into two category: a 
Wilkins score of ≥5 (severe remodeling / inflammation) and a Wilkins 
score <5 (minor remodeling / inflammation).20 There was no signifi-
cant relationship (p = 0.157) between this categorical Wilkins score 
and the RHD severity. This was due to the number of patients in the 
severe remodelling / inflammation group is only 1 patient, thus it is 
difficult to be statistically proven.
 Aloui et al. reported that the severity of valve thickening and 
calcification assessed by echocardiography using the Wilkins score were 
associated with high levels of Matrix metalloproteinase-3 (MMP-3). 
High levels of MMP-3, which is a marker of remodeling, are also 
positively correlated with the severity of the inflammatory process.15 
With a fairly high number of mitral valve abnormalities, there should be 
a significant relationship between Wilkins score and rheumatic valve 
severity. This was evident in the Wilkins bivariate test using numerical 
Wilkins score on the severity of RHD. The non significant relationship in 
Wilkins bivariate testing using categorical 2 groups was due to the low 
number of patients classified as severe remodeling / inflammation. This 
was not surprising because the subject of this study was taken from  all 
pediatric thus the process of chronic inflammation and remodeling of 
the heart valves has not been seen as clear and severe as in adult RHD 
patients.
 There were high number of patients with mitral valve 
regurgitation in our study, those involving only the mitral valve 
(70.2%) and those that coincided with the aortic valve (27.7%). 
Previous study by Mehta et al. (2013) found that mitral valve regurgita-
tion abnormalities were the most common valve abnormalities (48.7%) 
in RHD.21 Carapetis et al. also mentioned that valve thickening, thicken-
ing of the chorda tendinae, and tethering in one or both valves could 
occur, even in mild valve abnormalities. The mechanism most often was 
caused by mitral regurgitation in RHD cases.9
 The multivariate logistic regression analysis between the 
adherence to secondary prophylaxis, total ARF recurrence, and Wilkins 
scores demonstrated that adherence to secondary prophylaxis variable 
has the strongest relation to the severity of RHD (p = 0.049; OR 7.20). 
The magnitude of OR obtained is 7.20 which means that the likelihood 
of patients experiencing a degree of worsened RHD is 7.2 times higher 
in poor adherent compared to those adequate adherent patients.
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5. Conclusion
 Our study revealed that poor adherence to secondary 
prophylaxis is significantly associated with more severe rheumatic 
valve severity in pediatric patients. In addition, higher Wilkins score 
and higher rate of total ARF recurrence were significantly associated 
with rheumatic valve severity. The adherence to secondary prophylaxis 
has the strongest relation to the rheumatic valve severity compared to 
other factors. Therefore, higher level of adherence is required to 
prevent and reduce rheumatic mitral and/or aortic valve severity in 
pediatric patients in Indonesia.
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